How many modes of action should an antibiotic have?

Current Opinion in Pharmacology

Volumn 8, Issue 5, 2008, Pages 564-573

  Brötz Oesterhelt, Heike ^a   Brunner, Nina A ^a  

^a AiCuris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CYCLOSERINE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; NOVOBIOCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; SULFAMETHOXAZOLE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; DRUG BINDING; DRUG MECHANISM; ENZYME INHIBITION; GENE TARGETING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; HUMAN; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL;

EID: 54849413943     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.06.008     Document Type: Review

References (50)

1. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6 (2007) 29-40. Outstanding review critically describing the experiences of Glaxo with 70 target-based high-throughput screening campaigns.
2. Silver L.L. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6 (2007) 41-55. Highly instructive review supporting the concept of multiplicity of action for antibiotic therapy.
3. Lange R.P., Locher H.H., Wyss P.C., and Then R.L. The targets of currently used antibacterial agents: lessons for drug discovery. Curr Pharm Des 13 (2007) 3140-3154. Comprehensive analysis of the mechanisms of action of established antibiotics in the light of the recent literature.
4. Singh S.B., and Barrett J.F. Empirical antibacterial drug discovery - foundation in natural products. Biochem Pharmacol 71 (2006) 1006-1015
5. Scheffers D.J., and Pinho M.G. Bacterial cell wall synthesis: new insights from localization studies. Microbiol Mol Biol Rev 69 (2005) 585-607
6. Drlica K., Malik M., Kerns R.J., and Zhao X. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52 (2008) 385-392. Expert review compiles the current understanding and remaining questions of the complex antibacterial mechanism of quinolones.
7. Kahne D., Leimkuhler C., Lu W., and Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 105 (2005) 425-448
8. Xiong L., Kloss P., Douthwaite S., Andersen N.M., Swaney S., Shinabarger D.L., and Mankin A.S. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 182 (2000) 5325-5331
9. Schlunzen F., Zarivach R., Harms J., Bashan A., Tocilj A., Albrecht R., Yonath A., and Franceschi F. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413 (2001) 814-821
10. Connell S.R., Tracz D.M., Nierhaus K.H., and Taylor D.E. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 47 (2003) 3675-3681
11. Kaul M., Barbieri C.M., and Pilch D.S. Aminoglycoside-induced reduction in nucleotide mobility at the ribosomal RNA A-site as a potentially key determinant of antibacterial activity. J Am Chem Soc 128 (2006) 1261-1271
12. Klappenbach J.A., Saxman P.R., Cole J.R., and Schmidt T.M. rrndb: the Ribosomal RNA Operon Copy Number Database. Nucleic Acids Res 29 (2001) 181-184
13. Vester B., and Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 45 (2001) 1-12
14. Du W., Brown J.R., Sylvester D.R., Huang J., Chalker A.F., So C.Y., Holmes D.J., Payne D.J., and Wallis N.G. Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria. J Bacteriol 182 (2000) 4146-4152
15. Noda M., Kawahara Y., Ichikawa A., Matoba Y., Matsuo H., Lee D.G., Kumagai T., and Sugiyama M. Self-protection mechanism in d-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase and d-alanyl-d-alanine ligase, which are target enzymes of d-cycloserine. J Biol Chem 279 (2004) 46143-46152
16. Chopra I. Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. Curr Opin Investig Drugs 8 (2007) 600-607
17. Skold O. Sulfonamide resistance: mechanisms and trends. Drug Resist Updat 3 (2000) 155-160
18. Hawser S., Lociuro S., and Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71 (2006) 941-948
19. Hansson S., Singh R., Gudkov A.T., Liljas A., and Logan D.T. Structural insights into fusidic acid resistance and sensitivity in EF-G. J Mol Biol 348 (2005) 939-949
20. Maxwell A., and Lawson D.M. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 3 (2003) 283-303
21. Alekshun M.N., and Levy S.B. Molecular mechanisms of antibacterial multidrug resistance. Cell 128 (2007) 1037-1050
22. von Nussbaum F., Brands M., Hinzen B., Weigand S., and Habich D. Antibacterial natural products in medicinal chemistry - exodus or revival?. Angew Chem Int Ed Engl 45 (2006) 5072-5129. Recent summary of chemical approaches to improve the pharmacological profile of antibacterial natural products.
23. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G., and Then R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45 (2001) 825-836
24. Davies T.A., Page M.G., Shang W., Andrew T., Kania M., and Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 51 (2007) 2621-2624
25. Bonnefoy A., Girard A.M., Agouridas C., and Chantot J.F. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 40 (1997) 85-90
26. Poehlsgaard J., and Douthwaite S. Macrolide antibiotic interaction and resistance on the bacterial ribosome. Curr Opin Investig Drugs 4 (2003) 140-148
27. Maravic G. Macrolide resistance based on the Erm-mediated rRNA methylation. Curr Drug Targets Infect Disord 4 (2004) 193-202
28. Berisio R., Harms J., Schluenzen F., Zarivach R., Hansen H.A., Fucini P., and Yonath A. Structural insight into the antibiotic action of telithromycin against resistant mutants. J Bacteriol 185 (2003) 4276-4279
29. Olson M.W., Ruzin A., Feyfant E., Rush III T.S., O'Connell J., and Bradford P.A. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 50 (2006) 2156-2166
30. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., and Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43 (1999) 738-744
31. Schneider P., Hawser S., and Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 13 (2003) 4217-4221
32. Higgins D.L., Chang R., Debabov D.V., Leung J., Wu T., Krause K.M., Sandvik E., Hubbard J.M., Kaniga K., Schmidt Jr. D.E., et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 1127-1134
33. Allen N.E., and Nicas T.I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 26 (2003) 511-532
34. Kim S.J., Cegelski L., Stueber D., Singh M., Dietrich E., Tanaka K.S., Parr Jr. T.R., Far A.R., and Schaefer J. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 377 (2008) 281-293
35. Greenwood D., and O'Grady F. Dual-action cephalosporin utilizing a novel therapeutic principle. Antimicrob Agents Chemother 10 (1976) 249-252
36. Bremner J.B., Ambrus J.I., and Samosorn S. Dual action-based approaches to antibacterial agents. Curr Med Chem 14 (2007) 1459-1477. Comprehensive introduction into the chemical and pharmacological concepts of hybrid molecules.
37. Bryskier A. Dual beta-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment. Expert Opin Investig Drugs 6 (1997) 1479-1499. Multifarious analysis of prospects and pitfalls of fluoroquinolone-β-lactam hybrids.
38. Pace J., Bertasso A., and Georgopapadakou N.H. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424. Antimicrob Agents Chemother 35 (1991) 910-915
39. Butler M.M., Lamarr W.A., Foster K.A., Barnes M.H., Skow D.J., Lyden P.T., Kustigian L.M., Zhi C., Brown N.C., Wright G.E., and Bowlin T.L. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother 51 (2007) 119-127
40. Hanessian S., and Kothakonda K.K. 3-N,N-Dimethylamino-3-deoxy lincomycin: a structure-based hybrid between lincomycin and the desosamine unit of erythromycin. Bioorg Med Chem 13 (2005) 5283-5288
41. Stone G.W., Zhang Q., Castillo R., Doppalapudi V.R., Bueno A.R., Lee J.Y., Li Q., Sergeeva M., Khambatta G., and Georgopapadakou N.H. Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by beta-lactamases. Antimicrob Agents Chemother 48 (2004) 477-483
42. Hubschwerlen C., Specklin J.L., Baeschlin D.K., Borer Y., Haefeli S., Sigwalt C., Schroeder S., and Locher H.H. Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action. Bioorg Med Chem Lett 13 (2003) 4229-4233
43. Gray C., Moes L., Locher H., and Dale G. Characterization of MCB 3681, a dual-action antibiotic. Intersci Conf Antimicrob Agents Chemother 45 (2005) F512
44. Kresken M., and Brauers J. In vitro activity of the novel antibacterial MCB 3681 against selected Gram-positive and -negative bacteria compared to established antibiotics. Intersci Conf Antimicrob Agents Chemother 46 (2006) F1-1967
45. Robertson G.T., Bonventre E.J., Doyle T.B., Du Q., Duncan L., Morris T.W., Roche E.D., Yan D., and Lynch A.S. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies undertaken in Staphylococci and Streptococci. Antimicrob Agents Chemother 52 (2008) 2324-2334
46. Robertson G.T., Bonventre E.J., Doyle T.B., Du Q., Duncan L., Morris T.W., Roche E.D., Yan D., and Lynch A.S. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother 52 (2008) 2313-2323
47. Krause K.M., Difuntorum S., Blais J., Turner S.D., and Marquess D. TD-1792, a new antibiotic with improved in vitro activity. Intersci Conf Antimicrob Agents Chemother 47 (2007) E-1626
48. Difuntorum S., Blais J., Hedge S.S., Skinner R., Reyes N., Trumbull J., Turner S.D., and Marquess D. In vitro and in vivo evidence for a multivalent mode of action of TD-1792 against Staphylococcus aureus. Intersci Conf Antimicrob Agents Chemother 47 (2007) F1-2110
49. O'Shea R., and Moser H.E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51 (2008) 2871-2878. First analysis of the physicochemical requirements of antibiotics separated by Gram-positives, Gram-negatives, and Pseudomonas-active compounds.
50. Freiberg C., Brotz-Oesterhelt H., and Labischinski H. The impact of transcriptome and proteome analyses on antibiotic drug discovery. Curr Opin Microbiol 7 (2004) 451-459